Senti Biosciences, Inc. - Common Stock SNTI 深 沪
等待开盘 11-01 09:30:00 美东时间
2.03
-0.090
-4.25%
华盛通- 最 高2.1502
- 今 开2.15
- 成交量 6.76万股
- 最 低 2.00
- 昨 收 2.12
- 总市值 5310.52万
- 52周最高 16.94
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 1.26
- 委 比 40.79%
- 总股本 2616.02万
- 历史最高 87.70
- 量 比 0.73
- 振 幅 7.08%
- 历史最低 1.26
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
Senti Biosciences, Inc. announced that its CEO, Timothy Lu, will present at the 9th Annual Genetic Medicines Conference on October 21, 2025. The live presentation will be webcast on the company’s website. Senti Bio, a clinical-stage biotech company, develops next-generation cell and gene therapies using its proprietary Gene Circuit platform to target incurable diseases, with a focus on cancer treatments. The platform aims to enhance precision and...
10-16 13:05
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
HC Wainwright & Co. Initiates Coverage On Senti Biosciences with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Price Target of $12.
10-14 19:48
Senti Bio to Present at BioJapan
Senti Biosciences will present at BioJapan 2025 in Yokohama, Japan, on October 9th at 11:30 AM JST. Timothy Lu, CEO and Co-Founder, will deliver the presentation. Senti Bio is a clinical-stage biotech company leveraging its Gene Circuit platform to develop next-generation cell and gene therapies for incurable diseases. The company will also host one-on-one meetings and a booth at the event. For more details, visit the conference website.
10-06 13:05
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
Senti Biosciences announced that its President and Chief Medical Officer, Kanya Rajangam, will present at the MedInvest Biotech & Pharma Conference on September 24, 2025. The presentation will focus on the company’s next-generation cell and gene therapies developed using its proprietary Gene Circuit platform. A live webcast of the presentation will be available on the company’s website. Senti Bio leverages its synthetic biology platform to engine...
09-18 13:15
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, announced that its Co-Founder and CEO, Dr. Timothy Lu, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 PM ET. The presentation will include a live video webcast available on the company's website, with a replay archived for 90 days. Additionally, management will conduct one-on-one meetings with qua...
09-02 13:05
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Senti Bio, a clinical-stage biotech company, will present at Webull Financial's Biotech/MedTech webinar on August 19, 2025, at 2:20 PM ET. Timothy Lu, MD, PhD, CEO and Co-Founder of Senti Bio, will deliver the presentation. The event will feature insights into Senti Bio's Gene Circuit platform, which enables next-generation cell and gene therapies for incurable diseases. Registration is available at the provided link. For more details, visit Sent...
08-14 13:15
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Senti Bio, a clinical-stage biotechnology company, participated in a Virtual Investor “What This Means” segment where Kanya Rajangam, M.D., Ph.D., discussed the recommended Phase 2 dose selection for their potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, targeting relapsed/refractory hematologic malignancies, including AML. The Company leverages its synthetic biology Gene Circuit platform to engineer precise and ...
08-12 13:15
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
